US20220016122A1 - SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT - Google Patents

SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT Download PDF

Info

Publication number
US20220016122A1
US20220016122A1 US17/490,318 US202117490318A US2022016122A1 US 20220016122 A1 US20220016122 A1 US 20220016122A1 US 202117490318 A US202117490318 A US 202117490318A US 2022016122 A1 US2022016122 A1 US 2022016122A1
Authority
US
United States
Prior art keywords
pyrazolo
dihydro
quinazoline
amino
diethylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/490,318
Inventor
Massimo Zampieri
Marina Caldarelli
Ilaria Candiani
Matteo D'Anello
Germano D'Arasmo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Priority to US17/490,318 priority Critical patent/US20220016122A1/en
Assigned to NERVIANO MEDICAL SCIENCES S.R.L. reassignment NERVIANO MEDICAL SCIENCES S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LES LABORATOIRES SERVIER
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZAMPIERI, MASSIMO, D'ARASMO, GERMANO, CANDIANI, ILARIA, CALDARELLI, MARINA, D'ANELLO, MATTEO
Publication of US20220016122A1 publication Critical patent/US20220016122A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a new salt of N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethyl amino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide of formula (I):
  • N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[ 4 , 3 -]quinazoline-3-carboxamide has very valuable pharmacological properties in the field of oncology.
  • N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide has the ability to inhibit MPS1 (Monopolar Spindle 1) kinase, also known as TTK (Tyrosine and Serine/Threonine kinase). This ability confers to the molecule therapeutic benefit in the treatment of several diverse cancers, cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders.
  • MPS1 Monopolar Spindle 1 kinase
  • TTK Teyrosine and Serine/Threonine kinase
  • carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma.
  • T-cell-lymphoma Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like
  • cell proliferative disorder envisaged for treatment there may be mentioned, without implying any limitation, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • the present invention accordingly relates to a new salt of N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, more especially N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin- 1 -yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II):
  • the invention relates also to a process for obtaining N-(2,6-diethylphenyI)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
  • the compound of formula (II) according to the invention has a good stability over time under denaturing conditions (40° C./75% Relative Humidity (RH)):
  • Solubility target solution 1 hour 24 hours concentration in water (mg/ml as (mg/ml as Compound (mg/ml as free base) free base) free base) Free Base 10.0 ⁇ 0.001 ⁇ 0.001 In situ HCl salt 27.6 1.05 0.87 In situ phosphate 27.5 >24.3 >24.7 salt
  • the phosphate salt was identified during the salt screening as improving significantly the solubility of the drug substance while having a low propensity to hygroscopicity as demonstrated by Dynamic Vapour Sorption analysis below:
  • the last step of the process used to obtain compound of formula (II) can be performed in an organic solvent, and more specifically polar solvent such as for example THF (tetrahydrofurane), EtOH, MeOH, (1- or 2-) propanol, (1- or 2-) butanol, tertbutanol, 2-methoxyethanol, dioxane, ethyl acetate, isopropyl acetate, acetonitrile, acetone, MTBE (methyltertbutylether), MIBK (methylisobutylketone), DMSO (dimethylsulfoxide) and mixtures thereof.
  • polar solvent such as for example THF (tetrahydrofurane), EtOH, MeOH, (1- or 2-) propanol, (1- or 2-) butanol, tertbutanol, 2-methoxyethanol, dioxane, ethyl acetate, isopropyl acetate, acetonitrile
  • This new form I is characterized by the following Bragg's angles 2-theta (expressed in ° ⁇ 0.2) obtained from the X-ray powder diffractogram: 2.76, 8.10, 10.79, 13.49, 16.13, 17.37, 17.62, 19.77,21.94, 24.18, 24.66.
  • the last step of the process used to obtain compound of formula (II) is performed in water leading to a new hydrated polymorphic form named form II.
  • This new form II is characterized by the following Bragg's angles 2-theta (expressed in ° ⁇ 0.2) obtained from the X-ray powder diffractogram: 9.43, 9.86, 12.23, 13.70, 14.81, 18.01, 19.78, 20.73, 24.55, 24.82, 26.81.
  • the invention relates also to pharmaceutical compositions comprising as active ingredient the compound of formula (II) according to the invention, together with one or more inert, non-toxic, appropriate excipients.
  • pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or dragées, granules, sublingual tablets, capsules, lozenges, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions and chewing gums.
  • carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogen
  • cell proliferative disorder envisaged for treatment there may be mentioned, without implying any limitation, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • the useful dosage can be varied according to the nature and severity of the disorder, the administration route and the age and weight of the patient.
  • the dosage varies from 1 mg to 1 g per day, in terms of the free base equivalent, in one or more administrations.
  • FIG. 1 describes the X-ray diffraction diagram of amorphous form of the free base N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide.
  • FIG. 2 describes the X-ray diffraction diagram of form I of the N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
  • FIG. 3 describes the DSC diagram of form I of the N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
  • FIG. 4 describes the X-ray diffraction diagram of form II of the N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[ 9 4,3-h]quinazoline-3-carboxamide phosphate.
  • FIG. 5 describes the DSC diagram of form II of the N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
  • Step A 8-([4-Bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
  • Step B N-(2,6-Diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazollne-3-carboxamide phosphate, Form I
  • step A 0.55 kg of 8-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide obtained in step A are charged in a reactor with 6 L of THF. To the stirred mixture, 3.3 g of palladium acetate and 13.7 g of RuPhos in 3.9 L THF are added at room temperature under nitrogen.
  • reaction mixture is stirred at 50° C. for 4.5 hours and then cooled to room temperature. 12 L of water are added; phases are separated and the aqueous one is extracted once with 7 L of MTBE.
  • the organic phases are washed with brine and then extracted twice with 10% citric acid aqueous solution.
  • the citric acid phases are pooled and added with a 2/1 mixture of MTBE/THF.
  • the biphasic mixture is cooled to 10° C. and 35% aqueous NaOH is added until pH 9.
  • the organic phase is separated and treated with SPM32 resin at reflux.
  • the resin is filtered away washing with 2/1 mixture of MTBE/THF and the solvent is partially evaporated.
  • Absolute Ethanol is added and evaporated; the procedure is repeated and then 12 L of absolute ethanol are added.
  • the obtained solution is heated at 60° C. and a solution of 67 mL of 85% H 3 PO 4 mixed with 0.6 L of absolute ElOH is added dropwise.
  • a solution is kept until about half addition, and then a precipitate forms.
  • the suspension is heated to reflux (78.0° C.) for 18 minutes and then cooled to 23° C. in 1 hour and 25 minutes.
  • the suspension is further cooled to 5° C. in 1 hour and kept at 5° C. for 22.5 hours.
  • the title compound is isolated by filtration; the wet cake is washed with 2.5 L of absolute EtOH and dried under vacuum at 50° C. till constant weight.
  • the title compound is obtained in the form of a yellow powder.
  • Step A N-(2,6-Diethylphenyl-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (free base)
  • the organic phase is treated with 2.8 g of activated charcoal; the mixture is filtered on a dicalite pad, evaporated to dryness and purified by silica-gel chromatography eluting with DCM/EtOH/NH 3 95:5:0.5.
  • the pooled fractions are evaporated to residue, dissolved in EtOAc, washed five times with a saturated solution of sodium bicarbonate and with water, and then evaporated to dryness.
  • the product is dried in oven at 50° C. for 7 hours, and at 40° C. for 64 hours.
  • the free base is obtained as an amorphous yellow powder and characterized by its X-Ray diffraction diagram (see FIG. 1 ).
  • Step B N-(2,6-Diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate, Form I
  • the resulting suspension was heated to reflux (bath temperature 82-84° C.) for 5 minutes, then it was allowed to cool spontaneously to room temperature over a period of 2 hours and finally aged at +4° C. for 16 hours.
  • the solid was isolated by filtration, washed with 17.5 mL of ethanol on the filter and dried at +50° C. under vacuum for 10 hours yielding the title compound in the form of a yellow powder.
  • This instrument is based on Bragg-Brentano geometry and equipped with a Cu K ⁇ generator working at 45 KV/40 mA (1.8 kW power) and a Peltier-cooled solid state detector.
  • the spectral range w-as from 2 to 40° 2 ⁇ with a continuous scan acquisition at a rate of 1.20° 2 ⁇ /min.
  • the samples were loaded on Silicon low background plates.
  • the powder was flattened inside the holder by gently pressing with a microscope glass slide or other suitable tools.
  • Bragg's angles 2-theta (expressed in ° ⁇ 0.2) characteristic of the X-ray powder diffraction diagram are as follows: 2.76, 8.10, 10.79, 13.49, 16.13, 17.37, 17.62, 19.77, 21.94, 24.18, 24.66.
  • the title compound of Examples 1 and 2 was also characterised by its DSC diagram, carried out with a Perk in-Elmer DSC-7, using 50 ⁇ L vented aluminum DSC pans loaded with about 2-4 mg of sample. An aluminum disc was placed over the powder obtaining a thin layer and improving thermal exchange. The reference was a void pan of the same kind. Indium, Tin and Lead (LGC certified reference materials) were used to assess the calibration of the apparatus with regard to the temperature scale and the enthalpy response. The samples were analyzed under nitrogen flow at a healing rate of 10° C./min. Onset and peak temperatures (° C.) were generally considered parameters of interest. The diagram obtained is shown in FIG. 3 with an onset of melting of 229° C.
  • Thermo/ARL XTRA apparatus Thermo/ARL XTRA apparatus. This instrument is based on Bragg-Brentano geometry and equipped with a Cu K ⁇ generator working at 45 KV/40 mA (1.8 kW power) and a Peltier-cooled solid state detector. The spectral range was from 2 to 40° 2 ⁇ with a continuous scan acquisition at a rale of 1.20° 2 ⁇ /min which makes it possible to identify the following crystal parameters:
  • the title product was also characterised by its X-ray powder diffraction diagram shown in FIG. 4 carried out using a Thermo/ARL XTRA apparatus.
  • This instrument is based on Bragg-Brenlano geometry and equipped with a Cu K ⁇ generator working at 45 KV/40 mA (1.8 kW power) and a Peltier-cooled solid slate detector.
  • the spectral range was from 2 to 40° 2 ⁇ with a continuous scan acquisition at a rate of 1.20° 2 ⁇ /min.
  • the samples were loaded on Silicon low background plates.
  • the powder was flattened inside the holder by gently pressing with a microscope glass slide or other suitable tools.
  • Bragg's angles 2-theta (expressed in ° ⁇ 0.2) characteristic of the X-ray powder diffraction diagram: 9.43, 9.86, 12.23, 13.70, 14.81, 18.01, 19.78, 20.73, 24.55, 24.82, 26.81.
  • Example 3 The compound of Example 3 was also characterised by its DSC diagram, carried out with a Perkin-EImer DSC-7, using 50 ⁇ L vented aluminum DSC pans loaded with about 2-4 mg of sample. An aluminum disc was placed over the powder obtaining a thin layer and improving thermal exchange. The reference was a void pan of the same kind. Indium, Tin and Lead (LGC certified reference materials) were used to assess the calibration of the apparatus with regard to the temperature scale and the enthalpy response. The samples were analyzed under nitrogen flow at a heating rate of 10° C./min. Onset and peak temperatures (° C.) were generally considered parameters of interest.
  • LGC certified reference materials Indium, Tin and Lead
  • the diagram obtained is shown in FIG. 5 .
  • EXAMPLE 4 PURITY AND STABILITY of N-(2,6-diethylphenyl)-8-( ⁇ 4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl ⁇ amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate FORM I UNDER LONG TERM CONDITIONS
  • testing compound were suspended in 4 ml of WFI (water for injection) or Saline (0.9% NaCl) to test a target solubility of 150 mg/ml as free base.
  • the suspensions were magnetically stirred for 24 hours at room temperature and protected from light in amber glass vial. Testing compound concentrations were determined after 1 and 24 hours.
  • the compound to be tested is submitted to hygroscopicity test by means of a Dynamic Vapour Sorption apparatus (DVS 1000—Surface Measurement Systems).
  • the apparatus is briefly defined as a “controlled atmosphere microbalance” where the weighed sample is exposed to variations of the relative humidity (RH) at a constant and controlled temperature. An exactly weighed amount of the product (generally 5-10 mg) was analysed.
  • RH relative humidity
  • Example 1 1000 tablets each containing a dose of 35 mg of Example 1 . . . 100 g Wheat starch . . . 20 g Maize starch . . . 20 g
  • a bulk solution containing compound of Example 1, mannitol and Tween 80 is prepared, then lyophilized to obtain vials containing each 35 mg of compound of Example I, 300 mg of mannitol and 5 mg of Tween 80.
  • Lyophilisate is re-suspended in 10 ml of water for injection.

Abstract

N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II):
Figure US20220016122A1-20220120-C00001
Medicinal products containing the same which are useful in treating cancer, cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders.

Description

  • The present invention relates to a new salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethyl amino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide of formula (I):
  • Figure US20220016122A1-20220120-C00002
  • to its preparation process and also to pharmaceutical compositions containing it.
  • N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-]quinazoline-3-carboxamide has very valuable pharmacological properties in the field of oncology. It has in fact been shown that N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide has the ability to inhibit MPS1 (Monopolar Spindle 1) kinase, also known as TTK (Tyrosine and Serine/Threonine kinase). This ability confers to the molecule therapeutic benefit in the treatment of several diverse cancers, cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders. Among the cancers envisaged for treatment there may be mentioned, without implying any limitation, carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma. T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MAD1, BUB1, BUBR1, BUB3 and others.
  • Among the cell proliferative disorder envisaged for treatment there may be mentioned, without implying any limitation, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • The preparation and therapeutic use of N-(2,6-diethylphenyl)-8-({4-[4-(dimethyl amino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide have been described, for example, in the European patent specification EP2303891, the content of which is incorporated by reference.
  • In view of the pharmaceutical value of this compound it is important to be able to obtain the active compound in excellent yields, with high purity and with excellent reproducibility. Furthermore, taking into account the intravenous way of administration, it is also crucial to have very good solubility properties. It was rapidly found that the base described in the prior art presented problems of purification resulting in non-optimal purity, and presented also poor solubility. After numerous research studies, it was possible to identify a new salt combining various advantages, especially relating to purification, to reproducibility of the process for obtaining it and to yield, but also unexpectedly having the advantage of very significantly improving the solubility of the active compound. Furthermore, although much more water soluble, this new salt doesn't exhibit higher hygroscopicity than the free base. This new salt accordingly has all the qualities essential to its use as a medicament, from both the physicochemical and the pharmacokinetic point of view.
  • The present invention accordingly relates to a new salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, more especially N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II):
  • Figure US20220016122A1-20220120-C00003
  • This new salt has the following advantages:
      • a simple and reproducible process for obtaining it with excellent yield;
      • a high chemical purity, and low hygroscopicity;
      • an increased solubility in both water and physiologic serum, making it of great interest for intravenous administration.
  • The invention relates also to a process for obtaining N-(2,6-diethylphenyI)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
  • For example, it can be started from the starting material ethyl 8-[(4-bromo-2-methoxy phenyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate, as obtained in EP 2303891, which is reacted with 2,6-diethylaniline in presence of a strong base to give 8-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, which is then reacted with N,N-dimethylpiperidin-4-amine to yield compound of formula (I) that is then mixed with 1 to 2 equivalents of an H3PO4 solution to give N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II).
  • The compound of formula (II) according to the invention has a good stability over time under denaturing conditions (40° C./75% Relative Humidity (RH)):
  • 1 month 40° C./75% RH
    t0 Open bottle
    Phosphate salt of 99.5 99.4
    formula (II)
    Chemical purity in %
  • It has been established that the new salt of the invention had also improved solubility properties:
      • in preliminary test, in situ salt formation from the amorphous base at room temperature indicated that the phosphate salt had the capacity to improve solubility at least 25 times more than the hydrochloride salt and at least 24 000 times more than the free base:
  • Solubility
    target solution 1 hour 24 hours
    concentration in water (mg/ml as (mg/ml as
    Compound (mg/ml as free base) free base) free base)
    Free Base 10.0 <0.001 <0.001
    In situ HCl salt 27.6 1.05 0.87
    In situ phosphate 27.5 >24.3 >24.7
    salt
      • further investigations with the crystalline form I of the phosphate salt of formula (II) indicated a solubility at room temperature of at least 130 mg/ml expressed as free base, both in water and in NaCl 0.9%:
  • target solution
    concentration in Solubility
    water or NaCl 1 hour 24 hours
    (mg/ml as free (mg/ml as (mg/ml as
    Compound Medium base) free base) free base)
    Free Base water 10.0 <0.001 <0.001
    Phosphate salt water 150.0 87.5 130.2
    Phosphate salt NaCl 0.9% 150.0 81.0 133.6
  • The phosphate salt was identified during the salt screening as improving significantly the solubility of the drug substance while having a low propensity to hygroscopicity as demonstrated by Dynamic Vapour Sorption analysis below:
  • Water uptake at Water uptake at Water uptake at
    30% RH 60% RH 90% RH
    Free base 0.4 1 2.8
    Phosphate salt 0.4 1.0 2.5
  • In an advantageous alternative, the last step of the process used to obtain compound of formula (II) can be performed in an organic solvent, and more specifically polar solvent such as for example THF (tetrahydrofurane), EtOH, MeOH, (1- or 2-) propanol, (1- or 2-) butanol, tertbutanol, 2-methoxyethanol, dioxane, ethyl acetate, isopropyl acetate, acetonitrile, acetone, MTBE (methyltertbutylether), MIBK (methylisobutylketone), DMSO (dimethylsulfoxide) and mixtures thereof.
  • In that case, the compound of formula (II) obtained is characterised by the polymorphic form named form I.
  • This new form I is characterized by the following Bragg's angles 2-theta (expressed in °±0.2) obtained from the X-ray powder diffractogram: 2.76, 8.10, 10.79, 13.49, 16.13, 17.37, 17.62, 19.77,21.94, 24.18, 24.66.
  • In another advantageous alternative, the last step of the process used to obtain compound of formula (II) is performed in water leading to a new hydrated polymorphic form named form II.
  • This new form II is characterized by the following Bragg's angles 2-theta (expressed in °±0.2) obtained from the X-ray powder diffractogram: 9.43, 9.86, 12.23, 13.70, 14.81, 18.01, 19.78, 20.73, 24.55, 24.82, 26.81.
  • The invention relates also to pharmaceutical compositions comprising as active ingredient the compound of formula (II) according to the invention, together with one or more inert, non-toxic, appropriate excipients. Among the pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or dragées, granules, sublingual tablets, capsules, lozenges, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions and chewing gums.
  • The pharmaceutical forms comprising the compound of formula (II) according to the invention, will be used in the treatment of cancers, cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders. Among the cancers envisaged for treatment there may be mentioned, without implying any limitation, carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocylic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma, mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MAD1, BUB1, BUBR1, BUB3 and others.
  • Among the cell proliferative disorder envisaged for treatment there may be mentioned, without implying any limitation, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • The useful dosage can be varied according to the nature and severity of the disorder, the administration route and the age and weight of the patient. The dosage varies from 1 mg to 1 g per day, in terms of the free base equivalent, in one or more administrations.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 describes the X-ray diffraction diagram of amorphous form of the free base N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide.
  • FIG. 2 describes the X-ray diffraction diagram of form I of the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
  • FIG. 3 describes the DSC diagram of form I of the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
  • FIG. 4 describes the X-ray diffraction diagram of form II of the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[9 4,3-h]quinazoline-3-carboxamide phosphate.
  • FIG. 5 describes the DSC diagram of form II of the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate.
    •
  • The Examples hereinbelow illustrate the invention but do not limit it in any way.
    • EXAMPLE 1: N-(2,6-Diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate, FORM I Step A: 8-([4-Bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
  • To a solution containing 2.32 kg of 8-[(4-bromo-2-methoxyphenyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide in 34.8 L of THF is added 0.877 L of 2,6-diethylaniline. 15.2 L of LiHMDS are then added dropwise at −10° C. Reaction is stirred 1.5 hour, and LiHMDS is added until completion. Then 30.17 L of a NaCl solution are added and the organic phase is washed twice with NaCl solution, and evaporated. A solution of water/acetone is then added to the residue, and the solution refluxed, then cooled at 5° C. The precipitate is then filtered to give the title product as a light yellow powder.
  • Melting point: 218-220° C.
  • MS calc.: 561.1608; MS found. 561.1591
    • Step B: N-(2,6-Diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazollne-3-carboxamide phosphate, Form I
  • 0.55 kg of 8-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide obtained in step A are charged in a reactor with 6 L of THF. To the stirred mixture, 3.3 g of palladium acetate and 13.7 g of RuPhos in 3.9 L THF are added at room temperature under nitrogen.
  • 0.15 kg of 4-dimethylamino-piperidine are added to the reaction mixture with 0.55 L of THF, the internal temperature is increased to 50° C. and 3.9 L of 1M LiHMDS in THF are dropped.
  • The reaction mixture is stirred at 50° C. for 4.5 hours and then cooled to room temperature. 12 L of water are added; phases are separated and the aqueous one is extracted once with 7 L of MTBE.
  • The organic phases are washed with brine and then extracted twice with 10% citric acid aqueous solution. The citric acid phases are pooled and added with a 2/1 mixture of MTBE/THF. The biphasic mixture is cooled to 10° C. and 35% aqueous NaOH is added until pH 9. The organic phase is separated and treated with SPM32 resin at reflux. The resin is filtered away washing with 2/1 mixture of MTBE/THF and the solvent is partially evaporated. Absolute Ethanol is added and evaporated; the procedure is repeated and then 12 L of absolute ethanol are added. The obtained solution is heated at 60° C. and a solution of 67 mL of 85% H3PO4 mixed with 0.6 L of absolute ElOH is added dropwise. A solution is kept until about half addition, and then a precipitate forms. The suspension is heated to reflux (78.0° C.) for 18 minutes and then cooled to 23° C. in 1 hour and 25 minutes. The suspension is further cooled to 5° C. in 1 hour and kept at 5° C. for 22.5 hours. The title compound is isolated by filtration; the wet cake is washed with 2.5 L of absolute EtOH and dried under vacuum at 50° C. till constant weight. The title compound is obtained in the form of a yellow powder.
  • Melting point 220-223° C. with decomposition.
    • EXAMPLE 2: N-(2,6-Diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate, FORM I Step A: N-(2,6-Diethylphenyl-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (free base)
  • A solution, containing 213 mg of Pd(OAc)2 and 897 mg of RuPhos in 177 mL of THF, is added to 21.53 g of 8-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide obtained I Step A of Example 1 in 250 mL of THF, at room temperature under nitrogen. The mixture is heated at 40° C. before sequential addition of 152 mL of LiHMDS 1M in THF and 10.7 mL of N,N-dimethylpiperidin-4-amine. The reaction is kept at 40° C. for 2.5 hours and then cooled to room temperature. 300 mL of brine are then added and the organic separated phase is washed with 200 mL of brine.
  • The organic phase is treated with 2.8 g of activated charcoal; the mixture is filtered on a dicalite pad, evaporated to dryness and purified by silica-gel chromatography eluting with DCM/EtOH/NH3 95:5:0.5. The pooled fractions are evaporated to residue, dissolved in EtOAc, washed five times with a saturated solution of sodium bicarbonate and with water, and then evaporated to dryness. The product is dried in oven at 50° C. for 7 hours, and at 40° C. for 64 hours. The free base is obtained as an amorphous yellow powder and characterized by its X-Ray diffraction diagram (see FIG. 1).
    • Step B: N-(2,6-Diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate, Form I
  • 3.50 g of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide amorphous free base obtained in Step A, in 105 mL of absolute ethanol is heated to 60° C. under nitrogen. To this mixture a freshly prepared solution of 0.682 g of 85% phosphoric acid in 17.5 mL of ethanol was added dropwise over a period of 20 minutes under efficient stirring. The resulting suspension was heated to reflux (bath temperature 82-84° C.) for 5 minutes, then it was allowed to cool spontaneously to room temperature over a period of 2 hours and finally aged at +4° C. for 16 hours. The solid was isolated by filtration, washed with 17.5 mL of ethanol on the filter and dried at +50° C. under vacuum for 10 hours yielding the title compound in the form of a yellow powder.
  • Melting point 220-223° C. with decomposition.
  • The title product N-(2.6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate, Form I of Examples 1 and 2 is characterised by its X-ray powder diffraction diagram carried out using a Thermo/ARL XTRA apparatus, and shown in FIG. 2.
  • This instrument is based on Bragg-Brentano geometry and equipped with a Cu Kα generator working at 45 KV/40 mA (1.8 kW power) and a Peltier-cooled solid state detector. The spectral range w-as from 2 to 40° 2θ with a continuous scan acquisition at a rate of 1.20° 2θ/min. The samples were loaded on Silicon low background plates. The powder was flattened inside the holder by gently pressing with a microscope glass slide or other suitable tools.
  • The results are expressed in terms of nterplanar distance d, Bragg's angle 2 theta (expressed in °±0.2) and relative intensity (expressed as a percentage relative to the most intense line):
  • Pos. [°2Th.] d-spacing [Å] Rel. Int. [%]
    2.76 31.96 100.00
    8.10 10.90 37.71
    10.79 8.19 27.69
    13.49 6.56 35.45
    14.70 6.02 17.98
    14.79 5.98 12.17
    15.26 5.80 15.02
    15.47 5.72 15.26
    15.75 5.62 11.11
    16.13 5.49 57.81
    16.45 5.38 15.80
    17.37 5.10 22.52
    17.62 5.03 34.76
    17.80 4.98 27.97
    18.17 4.88 13.67
    19.77 4.49 20.09
    20.35 4.36 13.56
    21.94 4.05 24.02
    22.25 3.99 10.35
    23.61 3.77 19.98
    23.94 3.71 16.75
    24.18 3.68 26.62
    24.41 3.64 15.16
    24.66 3.61 25.6
    25.00 3.56 16.06
  • Bragg's angles 2-theta (expressed in °±0.2) characteristic of the X-ray powder diffraction diagram are as follows: 2.76, 8.10, 10.79, 13.49, 16.13, 17.37, 17.62, 19.77, 21.94, 24.18, 24.66.
  • The title compound of Examples 1 and 2 was also characterised by its DSC diagram, carried out with a Perk in-Elmer DSC-7, using 50 μL vented aluminum DSC pans loaded with about 2-4 mg of sample. An aluminum disc was placed over the powder obtaining a thin layer and improving thermal exchange. The reference was a void pan of the same kind. Indium, Tin and Lead (LGC certified reference materials) were used to assess the calibration of the apparatus with regard to the temperature scale and the enthalpy response. The samples were analyzed under nitrogen flow at a healing rate of 10° C./min. Onset and peak temperatures (° C.) were generally considered parameters of interest. The diagram obtained is shown in FIG. 3 with an onset of melting of 229° C.
    • EXAMPLE 3: N-(2,6-Diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate, tetrahydrate, FORM II
  • 304 mg of compound obtained in Step A of Example 2 are loaded in a three necks round bottom flask of 25 mL and 12 mL of water are added at room temperature. The suspension that is obtained is stirred while heating at 61-62° C.; pH is about 5.3. After 1 hour stirring, 35.9 μL of H3PO4 are added plus 5 mL of water and almost instantaneously everything get into solution and the pH lowered to 3.1. The solution is heated to 70° C. for 1 h in order to ensure complete dissolution, pH=3.2. The heating bath is removed and the vessel is left to cool to room temperature then stirred for 2 hours. The vessel is cooled to 5° C. by leaving it in the refrigerator overnight leading to a yellow precipitate crashing out of the solution. The solid was left to settle within the mixture at room temperature and the supernatant solution was removed. The remaining solid was dried in oven at 50° C. under vacuum for 18 h. The compound of the title was obtained as a yellow solid.
  • Broad dehydration endotherm : 35-125° C.
  • Exotherm of crystallisation (Tonset): 190° C.
  • The title product is characterised by its powder diffraction diagram, carried out using a Thermo/ARL XTRA apparatus. This instrument is based on Bragg-Brentano geometry and equipped with a Cu Kα generator working at 45 KV/40 mA (1.8 kW power) and a Peltier-cooled solid state detector. The spectral range was from 2 to 40° 2θ with a continuous scan acquisition at a rale of 1.20° 2θ/min which makes it possible to identify the following crystal parameters:
      • unit cell parameters: a=13.866(2) Å; b=18.824(2) Å; c=7.2575(7) Å; alpha=92.014(8)°; beta=91.813(7)°; gamma=107.294(8)°
      • space group: P-1 (2) (triclinic)
  • The title product was also characterised by its X-ray powder diffraction diagram shown in FIG. 4 carried out using a Thermo/ARL XTRA apparatus. This instrument is based on Bragg-Brenlano geometry and equipped with a Cu Kα generator working at 45 KV/40 mA (1.8 kW power) and a Peltier-cooled solid slate detector. The spectral range was from 2 to 40° 2θ with a continuous scan acquisition at a rate of 1.20° 2θ/min. The samples were loaded on Silicon low background plates. The powder was flattened inside the holder by gently pressing with a microscope glass slide or other suitable tools.
  • The results are expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2) and relative intensity (expressed as a percentage relative to the most intense line):
  • Pos. [°2Th.] d-spacing [Å] Rel. Int. [%]
    7.03 12.57 11.00
    9.43 9.37 56.04
    9.86 8.97 19.21
    12.23 7.23 22.55
    13.47 6.57 17.30
    13.70 6.46 27.62
    14.08 6.29 17.19
    14.23 6.19 12.02
    14.81 5.98 100.00
    15.36 5.77 11.17
    17.49 5.07 17.11
    18.01 4.92 30.83
    18.70 4.74 12.02
    19.78 4.48 52.48
    20.73 4.28 26.92
    22.85 3.89 15.52
    23.80 3.74 13.98
    24.55 3.62 21.43
    24.82 3.58 53.06
    25.91 3.44 15.20
    26.81 3.32 25.51
    27.16 3.28 10.01
    27.56 3.23 12.10
  • Bragg's angles 2-theta (expressed in °±0.2) characteristic of the X-ray powder diffraction diagram: 9.43, 9.86, 12.23, 13.70, 14.81, 18.01, 19.78, 20.73, 24.55, 24.82, 26.81.
  • The compound of Example 3 was also characterised by its DSC diagram, carried out with a Perkin-EImer DSC-7, using 50 μL vented aluminum DSC pans loaded with about 2-4 mg of sample. An aluminum disc was placed over the powder obtaining a thin layer and improving thermal exchange. The reference was a void pan of the same kind. Indium, Tin and Lead (LGC certified reference materials) were used to assess the calibration of the apparatus with regard to the temperature scale and the enthalpy response. The samples were analyzed under nitrogen flow at a heating rate of 10° C./min. Onset and peak temperatures (° C.) were generally considered parameters of interest.
  • The diagram obtained is shown in FIG. 5.
    • EXAMPLE 4: PURITY AND STABILITY of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate FORM I UNDER LONG TERM CONDITIONS
  • Purity and stability of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxy phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate Form I have been tested under long term conditions as follows:
  • Total amount Drug Crystalline
    of impurities substance Form (XRD
    Test Appearance (%) (%) assessment)
    t0 Yellow 0.06 99.94 Form I
    powder
    1 month 5° C. Yellow 0.06 99.94 Not tested
    powder
    1 month 25° C./ Yellow 0.07 99.93 Not tested
    60% RH powder
    3 months 5° C. Yellow 0.07 99.93 Not tested
    powder
    3 months 25° C./ Yellow 0.07 99.93 Not tested
    60% RH powder
    9 months 5° C. Yellow 0.07 99.93 Not tested
    powder
    12 months 5° C. Yellow 0.06 99.94 Form I
    powder
    24 months 5° C. Yellow 0.09 99.91 Form I
    powder
  • Results show that N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate Form I is stable at least up to 24 months.
    • EXAMPLE 5: Solubility of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate FORM I
  • Testing conditions: about 730 mg of testing compound were suspended in 4 ml of WFI (water for injection) or Saline (0.9% NaCl) to test a target solubility of 150 mg/ml as free base. The suspensions were magnetically stirred for 24 hours at room temperature and protected from light in amber glass vial. Testing compound concentrations were determined after 1 and 24 hours.
  • All the withdrawn suspension/solution amounts were centrifuged and the superior solutions were analysed by HPLC after filtration and dilution.
  • The obtained results arc summarized in the following table:
  • target solution
    concentration in Solubility
    water or NaCl 1 hour 24 hours
    (mg/ml as free (mg/ml as (mg/ml as
    Compound Medium base) free base) free base)
    Free Base water 10.0 <0.001 <0.001
    Phosphate salt water 150.0 87.5 130.2
    Phosphate salt NaCl 0.9% 150.0 81.0 133.6
    • EXAMPLE 6: Hygroscopicity measurement of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate, FORM I
  • The compound to be tested is submitted to hygroscopicity test by means of a Dynamic Vapour Sorption apparatus (DVS 1000—Surface Measurement Systems).
  • The apparatus is briefly defined as a “controlled atmosphere microbalance” where the weighed sample is exposed to variations of the relative humidity (RH) at a constant and controlled temperature. An exactly weighed amount of the product (generally 5-10 mg) was analysed.
  • Results are reported in the following Table:
  • Water uptake Water uptake Water uptake
    at 30% RH at 60% RH at 90% RH
    Free base 0.4 1 2.8
    Phosphate salt 0.4 1.0 2.5
    • EXAMPLE 7: PHARMACEUTICAL COMPOSITIONS A. Tablets
  • 1000 tablets each containing a dose of 35 mg of Example 1 . . . 100 g
    Wheat starch . . . 20 g
    Maize starch . . . 20 g
    • Lactose . . . 30 g
  • Magnesium stearate . . . 2 g
    • Silica . . . 1 g Hydroxypropylcellulose . . . 2 g B. Vials Lyophilisates
  • A bulk solution containing compound of Example 1, mannitol and Tween 80 is prepared, then lyophilized to obtain vials containing each 35 mg of compound of Example I, 300 mg of mannitol and 5 mg of Tween 80.
  • Lyophilisate is re-suspended in 10 ml of water for injection.

Claims (18)

1. A method of treating a condition selected from cancer, cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders in a subject in need thereof, comprising administration of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II):
Figure US20220016122A1-20220120-C00004
wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is administered alone or in combination with one or more pharmaceutically acceptable excipients.
2. The method according to claim 1, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate or formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form I.
3. The method according to claim 1, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form II.
4. The method according to claim 1, wherein the condition is selected from carcinoma, including bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma, mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MADI, BUB1, BUBR1, BUB3 and others; benign prostate hyperplasia; familial adenomatosis polyposis; neurofibromatosis; psoriasis; vascular smooth cell proliferation associated with atherosclerosis; pulmonary fibrosis; arthritis; glomerulonephritis and post-surgical stenosis and restenosis.
5. The method according to claim 4, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form I.
6. The method according to claim 4, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form II.
7. The method according to claim 1, wherein the condition is cancer and the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is administered in combination with radiotherapy.
8. The method according to claim 7, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form I.
9. The method according to claim 7, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form II.
10. A combination of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II):
Figure US20220016122A1-20220120-C00005
with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors and kinase inhibitors.
11. The combination according to claim 10, wherein the N-(1,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form I.
12. The combination according to claim 10, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form II.
13. A method of treating cancer in a subject in need thereof, comprising administration of the combination according to claim 10, optionally in combination with one or more pharmaceutically acceptable excipients.
14. The method according to claim 13, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form I.
15. The method according to claim 13, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form II.
16. A method of treating a condition selected from carcinoma including bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma, mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MAD1, BUB1, BUBR1, BUB3 and others; benign prostate hyperplasia; familial adenomatosis polyposis; neurofibromatosis; psoriasis; vascular smooth cell proliferation associated with atherosclerosis; pulmonary fibrosis; arthritis; glomerulonephritis and post-surgical stenosis and restenosis in a subject in need thereof, comprising administration of the combination according to claim 10, optionally in combination with one or more pharmaceutically acceptable excipients.
17. The method according to claim 16, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form I.
18. The method according to claim 16, wherein the N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II) is N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate in crystalline Form II.
US17/490,318 2017-06-29 2021-09-30 SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT Pending US20220016122A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/490,318 US20220016122A1 (en) 2017-06-29 2021-09-30 SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17305826 2017-06-29
EP17305826.4 2017-06-29
PCT/EP2018/067394 WO2019002454A1 (en) 2017-06-29 2018-06-28 New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it
US201916624488A 2019-12-19 2019-12-19
US17/490,318 US20220016122A1 (en) 2017-06-29 2021-09-30 SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2018/067394 Continuation WO2019002454A1 (en) 2017-06-29 2018-06-28 New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it
US16/624,488 Continuation US11160806B2 (en) 2017-06-29 2018-06-28 Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it

Publications (1)

Publication Number Publication Date
US20220016122A1 true US20220016122A1 (en) 2022-01-20

Family

ID=59313166

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/624,488 Active US11160806B2 (en) 2017-06-29 2018-06-28 Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it
US17/490,318 Pending US20220016122A1 (en) 2017-06-29 2021-09-30 SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/624,488 Active US11160806B2 (en) 2017-06-29 2018-06-28 Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it

Country Status (19)

Country Link
US (2) US11160806B2 (en)
EP (1) EP3645535B1 (en)
JP (1) JP7141416B2 (en)
KR (1) KR102609333B1 (en)
CN (1) CN110896636B (en)
AR (1) AR112040A1 (en)
AU (1) AU2018293729B9 (en)
BR (1) BR112019027924A2 (en)
CA (1) CA3068357C (en)
CL (1) CL2019003848A1 (en)
EA (1) EA039764B1 (en)
ES (1) ES2900048T3 (en)
IL (1) IL271628B2 (en)
MA (1) MA49498A (en)
PL (1) PL3645535T3 (en)
SG (1) SG11201912651WA (en)
TW (1) TWI750393B (en)
UY (1) UY37778A (en)
WO (1) WO2019002454A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines

Also Published As

Publication number Publication date
CN110896636B (en) 2022-07-19
US11160806B2 (en) 2021-11-02
AU2018293729B9 (en) 2022-07-14
IL271628A (en) 2020-02-27
AU2018293729A1 (en) 2020-01-23
EP3645535B1 (en) 2021-09-08
ES2900048T3 (en) 2022-03-15
AR112040A1 (en) 2019-09-11
EA202090115A1 (en) 2020-05-25
SG11201912651WA (en) 2020-01-30
KR102609333B1 (en) 2023-12-01
BR112019027924A2 (en) 2020-08-18
PL3645535T3 (en) 2022-03-21
JP2020525477A (en) 2020-08-27
UY37778A (en) 2019-01-31
KR20200020905A (en) 2020-02-26
AU2018293729B2 (en) 2022-03-10
CN110896636A (en) 2020-03-20
TWI750393B (en) 2021-12-21
EP3645535A1 (en) 2020-05-06
MA49498A (en) 2021-05-26
IL271628B2 (en) 2023-07-01
IL271628B1 (en) 2023-03-01
CA3068357A1 (en) 2019-01-03
EA039764B1 (en) 2022-03-11
WO2019002454A1 (en) 2019-01-03
CL2019003848A1 (en) 2020-07-10
US20200246339A1 (en) 2020-08-06
TW201904971A (en) 2019-02-01
CA3068357C (en) 2022-04-19
JP7141416B2 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
CN111148745B (en) Crystalline forms of FGFR inhibitors and methods of making the same
AU2022201061B2 (en) Novel Jak1 selective inhibitors and uses thereof
KR20180069132A (en) Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
CN110759908B (en) N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 protein and composition and application thereof
CN109689641B (en) Crystal form and salt form of substituted 2-hydrogen-pyrazole derivative and preparation method thereof
CN111362949B (en) Substituted pyrazolo [1,5-a ] pyrimidine compound, and pharmaceutical composition and application thereof
EP3741753A1 (en) Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof
KR20210024004A (en) Crystal forms of compounds for inhibiting the activity of CDK4/6 and uses thereof
US20220016122A1 (en) SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
WO2019228330A1 (en) Substituted benzo[d]imidazole compound and pharmaceutical composition thereof
CN113149960A (en) Crystal of salt of quinazoline derivative
CN113717245A (en) EGFR degradation agent containing 2,8, 9-trisubstituted-9H-purine structural fragment, and salt and application thereof
EP3750894B1 (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
WO2023093859A1 (en) Salt of axl kinase inhibitor, preparation method therefor and use thereof
TW202342041A (en) Pharmaceutical composition and method for preparing active ingredient compound thereof
US10577364B2 (en) Crystalline form of fused pyridine derivative&#39;s maleate and uses thereof
KR20220007447A (en) Compounds as a TRAP1 selective inhibitor, and composition for preventing or treating cancer comprising the same
CN117186062A (en) 4-carbonylaminoisoindoline-1, 3-dione compound, preparation method, pharmaceutical composition and application thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: NERVIANO MEDICAL SCIENCES S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LES LABORATOIRES SERVIER;REEL/FRAME:057844/0584

Effective date: 20200525

Owner name: LES LABORATOIRES SERVIER, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZAMPIERI, MASSIMO;CALDARELLI, MARINA;CANDIANI, ILARIA;AND OTHERS;SIGNING DATES FROM 20200109 TO 20200217;REEL/FRAME:057844/0397

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED